Showing results (1-10 of 43) with videos related to
Sort By:
Pageof 5
Cancer Research|January 20, 2004
F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cellValeria R Fantin, Philip LederCell|September 17, 2013
Self-eating limits EGFR-dependent tumor growthValeria R Fantin, Robert T AbrahamCurrent Opinion in Genetics & Development|November 30, 2010
Survival of the fittest: metabolic adaptations in cancerMarcelo J Berardi, Valeria R FantinClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implicationsValeria R Fantin, Victoria M RichonCancer Cell|June 13, 2006
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenanceValeria R Fantin, Julie St-Pierre, Philip LederCancer Cell|August 2, 2002
A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growthValeria R Fantin, Marcelo J Berardi, Luca Scorrano, et al.Nature|February 21, 2024
Natural killer cell therapiesEric Vivier, Lucas Rebuffet, Emilie Narni-Mancinelli, et al.Cancer Research|August 3, 2005
A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cellsValeria R Fantin, Marcelo J Berardi, Holger Babbe, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 21, 2016
Leveraging model-based study designs and serial micro-sampling techniques to understand the oral pharmacokinetics of the potent LTB4 inhibitor, CP-105696, for mouse pharmacology studiesMary E Spilker, Heekyung Chung, Ravi Visswanathan, et al.Nature Communications|September 26, 2014
Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretionNaval P Shanware, Kevin Bray, Christina H Eng, et al.Pageof 5